KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a world innovator in drug supply platforms, introduced that its company shopper Amari Corp.’s “Everyday Calm” CBD product was named a Top CBD Product Pick by New Hope Network, host of the industry-leading Natural Products Expo convention occasions. Hundreds of CBD merchandise competed to be amongst “New Hope Network editors’ Top Picks for 2020”.
Eric Gricus, CEO and Founder of Amari, commented, “Amari went through an extensive selection process for our CBD technology supplier. Lexaria exceeded our expectations for product quality, service, and pricing. We are thrilled to have the Lexaria team working with Amari to help us develop products our customers love and to win industry accolades.”
Lexaria’s DehydraTECHTM know-how delivers CBD extra shortly and successfully, as evidenced in repeated research, to boost shopper satisfaction and strengthen model loyalty.
“Lexaria is delighted to have been able to work with Amari and their award-winning products,” stated Chris Bunka, CEO of Lexaria. “DehydraTECH is gaining more widespread consumer support, and we expect to see products utilizing DehydraTECH technology in more and more stores across America as the year unfolds.”
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug supply know-how, DehydraTECH™, improves the way in which energetic pharmaceutical substances (APIs) enter the bloodstream by selling more healthy oral ingestion strategies and rising the effectiveness of fat-soluble energetic molecules, thereby decreasing total dosing. The Company’s know-how may be utilized to many various ingestible product codecs, together with meals, drinks, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the flexibility to extend bio-absorption by as much as 5-10x, scale back time of onset from 1 – 2 hours to minutes, and masks undesirable tastes; and is deliberate to be additional evaluated for orally administered bioactive molecules, together with anti-virals, cannabinoids, nutritional vitamins, non-steroidal anti-inflammatory medicine (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to a number of corporations, together with a world-leading tobacco producer, for the event of smokeless, oral-based nicotine merchandise and to be used in industries that produce cannabinoid drinks, edibles, and oral merchandise. Lexaria operates a licensed in-house analysis laboratory and holds a strong mental property portfolio with 18 patents granted and roughly 60 patents pending worldwide. For extra info, please go to www.lexariabioscience.com.
Founded in 2019, Amari was launched by outside fanatic Eric Gricus for folks like him. People who like to be energetic, however who might have seen as they grow old that the spirit is prepared, however the physique usually has aches and pains and soreness after a day of mountain climbing, snowboarding, or rafting. To create the product, Eric leveraged his greater than 10 years’ expertise working with early-stage CPG corporations and commercializing analysis from a college setting. Amari formulation mix science and know-how to offer genuine, plant-based treatments that ship tangible advantages to help a way of life of wellness and vitality whereas being rooted in transparency and intensive quality control.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press launch consists of forward-looking statements. Statements as such time period is outlined below relevant securities legal guidelines. These statements could also be recognized by phrases reminiscent of “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and different related expressions. Such forward-looking statements in this press launch embrace, however should not restricted to, statements by the corporate relating the Company’s capacity to hold out analysis initiatives, obtain regulatory approvals or grants, or expertise optimistic results or outcomes from any analysis or research. Such forward-looking statements are estimates reflecting the Company’s finest judgment primarily based upon present info and contain a variety of dangers and uncertainties, and there may be no assurance that the Company will really obtain the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you shouldn’t place undue reliance on these forward-looking statements. Factors which might trigger precise outcomes to vary materially from these estimated by the Company embrace, however should not restricted to, authorities regulation and regulatory approvals, managing and sustaining development, the impact of antagonistic publicity, litigation, competitors, scientific discovery, the patent utility, and approval course of, potential antagonistic results arising from the testing or use of merchandise using the DehydraTECH know-how, the Company’s capacity to keep up present collaborations and notice the advantages thereof, delays or cancellations of deliberate R&D that would happen associated to pandemics or for different causes, and different elements which can be recognized every so often in the Company’s public bulletins and periodic filings with the US Securities and Exchange Commission on EDGAR. There is not any assurance that any of Lexaria’s postulated makes use of, advantages, or benefits for the patented and patent-pending know-how will, in truth, be realized in any method or in any half. No assertion herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated merchandise should not supposed to diagnose, deal with, treatment or stop any illness. Any forward-looking statements contained in this launch communicate solely as of the date hereof, and the Company expressly disclaims any obligation to replace any forward-looking statements contained herein, whether or not as a results of any new info, future occasions, modified circumstances, or in any other case, besides as in any other case required by legislation.
The CSE has not reviewed and doesn’t settle for duty for the adequacy or accuracy of this launch.
SOURCE: Lexaria Bioscience Corp.